Skip to main content

New trial drug combination shows promise for slowing progression of ALS

A new drug combination tested in a multisite human clinical trial shows promise for slowing the progression of ALS, often called Lou Gehrig’s disease, researchers at the University of Florida and partner institutions reported in The New England Journal of Medicine.

The oral drug, a combination of sodium phenylbutyrate and taurursodiol, was tested in the Phase 2 CENTAUR trial, a placebo-controlled, randomized, double-blind trial of 137 ALS patients within 18 months of onset of symptoms. The compounds, which previously were found to reduce neuronal death in preclinical models, resulted in statistically significant slowing of disease progression in the human trial, according to the study.



from Department of Neurology » College of Medicine » University of Florida https://ift.tt/2Tjr3Zm
Labels:

Comments

Post a Comment

Popular posts from this blog

More Evidence that Patient Portals Improve Patient Care

Of all the medical specialties, neurologists see some of the most complex patients. This idea bears out anecdotally among the neurologists we have interviewed here at Neurology Insights but also statistically. In this 2018 study published in JAMA , neurologists were ranked #3 among physician types for patient complexity as well as for their number of comorbidities (Nephrologists were ranked #1, if you must know). Not surprisingly, among the comorbidities they listed: diabetes . In addition to the neurological sequelae associated with diabetes, this complex and chronic condition often requires well-coordinated care involving repeated testing and care by other providers. A new study published last month (June, 2019) in the journal PlosOne , shows that all this can be improved when these complex patients have access to a patient portal . “A patient portal is a secure online website that gives patients convenient, 24-hour access to personal health information from anywhere with an Inte...
Post a Comment
Read more